Xu Leyuan, Bai Qianming, Zhang Xin, Yang Hu
Department of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA 23284, United States; Department of Internal Medicine, Yale University, New Haven, CT 06520, United States.
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.
J Control Release. 2017 Apr 28;252:73-82. doi: 10.1016/j.jconrel.2017.02.023. Epub 2017 Feb 22.
Folate receptor (FR) is highly expressed in many types of human cancers, and it has been actively studied for developing targeted chemotherapy and diagnostic agents. Tremendous efforts have been made in developing FR-targeted nanomedicines and nanoprobes and translating them into clinical applications. This article provides a concise review on the latest development of folate-mediated nanomedicines and nanoprobes for chemotherapy and diagnostics with an emphasis on in vivo applications. The cellular uptake mechanisms, pharmacokinetics (PK), administration routes and major challenges in FR-targeted nanoparticles are discussed.
叶酸受体（FR）在多种人类癌症中高度表达，并且人们一直在积极研究开发靶向化疗药物和诊断试剂。在开发FR靶向纳米药物和纳米探针并将其转化为临床应用方面已经付出了巨大努力。本文简要综述了叶酸介导的纳米药物和纳米探针在化疗和诊断方面的最新进展，重点是体内应用。讨论了FR靶向纳米颗粒的细胞摄取机制、药代动力学（PK）、给药途径和主要挑战。
